---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-112662"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:26:51.338388+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools to consolidate R&D to Singapore, reduce US workforce, expects $3.6M in costs

## Summary
- Consolidates South San Francisco R&D into Singapore facility to co-locate with manufacturing.
- Reduction-in-force of certain US R&D employees, including management team members.
- Estimated total expenses of ~$3.6M, including ~$0.9M non-cash share-based award vesting.
- Restructuring costs expected to be payable over the next several months.

## SEC filing metadata
- accession: 0000950170-25-112662
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017025112662/0000950170-25-112662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017025112662/lab-20250828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-112662
- JSON: https://secwatch.observer/filing/0000950170-25-112662.json
- Plain text: https://secwatch.observer/filing/0000950170-25-112662.txt

## Source-grounded claims
- claim_id: 646207984015deb36b9b240edbe3c7fc060b77b2
  claim: STANDARD BIOTOOLS INC. announced a restructuring with charges of approximately $3.6 million affecting R&D function (reduction-in-force of certain U.S. employees in the Company’s R&D function, including members of its management team).
  evidence_excerpt: The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $3.6 million, which includes approximately $0.9 million of non-cash expenses related to vesting of share-based awards. These estimates are subject to a number of assumptions, and actual
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095017025112662/0000950170-25-112662-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.